HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Friedhelm Beyersdorf Georg Lutter Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heilmann, C. Articles by Lutter, G. Search for Related Content PubMed PubMed Citation Articles by Heilmann, C. Articles by Lutter, G. Related Collections Cardiac - other Coronary disease Molecular biology

Eur J Cardiothorac Surg 2002;22:957-964
© 2002 Elsevier Science NL

Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2

^a Department of Cardiovascular Surgery, Albert-Ludwigs-University Freiburg, Freiburg, Germany
^b Department of Surgical Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany

Received 5 May 2002; received in revised form 2 September 2002; accepted 4 September 2002.

* Corresponding author. Tel.: +49-761-270-2818; fax: +49-761-270-2550
e-mail: lutter{at}ch11.ukl.uni-freiburg.de

Objective: Treatment of coronary disease by growth factors has become an increasingly used strategy for otherwise untreatable patients and is subject to a number of clinical studies. The aim is to stimulate the development of a sufficient collateral circulation and hereby to rescue cardiac function. The objective of our study was to compare the effectiveness of fibroblast growth factor-2 (FGF-2) as protein and as naked plasmid DNA in a porcine model of chronic myocardial ischemia. Materials and methods: A severe stenosis of the left anterior descending artery (LAD) artery was created in healthy pigs. After 1 week, perfusion and regional and global contractility was assessed at baseline at rest and under stress. Afterwards, recombinant FGF-2 (n=6) or naked plasmid DNA encoding FGF-2 (n=7) was intramyocardially injected into the LAD territory. Control animals were left untreated (n=5). After 3 months, the animals were re-examined and underwent immunohistologic analysis. One animal received an Enhanced Green Fluorescent Protein plasmid. Results: Plasmid-dependent protein synthesis was present in cardiomyocytes. FGF-2 protein as well as plasmid injections resulted in an increased number of capillaries and of arterioles compared with untreated ischemia. The improvement of the regional myocardial blood flow by FGF-2 plasmid therapy at rest might however indicate the effectiveness of the DNA application for the induction of a collateral circulation. A benefit from FGF-2 plasmid therapy was revealed with regard to regional contractility. Systemic hemodynamics were partially improved following plasFGF-2 treatment. Conclusions: In this porcine model of chronic myocardial ischemia, intramyocardial injection of FGF-2 plasmid was more effective than of FGF-2 protein in improving regional perfusion and contractility compared to untreated ischemia.

Key Words: Coronary disease • Fibroblast growth factor-2 • Gene expression • Angiogenesis • Perfusion • Contractility

This article has been cited by other articles:

				C. Heilmann and F. Beyersdorf Editorial comment Growth factor therapy grows, despite limited insight. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 107 - 108. [Full Text] [PDF]

				R. Morishita, M. Aoki, and T. Ogihara Does gene therapy become pharmacotherapy? Exp Physiol, May 1, 2005; 90(3): 307 - 313. [Abstract] [Full Text] [PDF]

				C. A.U. Heilmann, T. Attmann, A. Thiem, E. Haffner, F. Beyersdorf, and G. Lutter Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 785 - 793. [Abstract] [Full Text] [PDF]